Last reviewed · How we verify
NCT05333055: DRAGONS
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
trial in Diabetic Retinopathy in 107 participants. Terminated before completion.
15 May 2024
Quick facts
| Lead sponsor | Greater Houston Retina Research |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 107 |
| Start date | 10 February 2022 |
| Primary completion | 15 May 2024 |
| Estimated completion | 15 May 2024 |
| Sites | 3 locations across United States |
Conditions studied
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
- Other Retinal Disorders — all drugs for Other Retinal Disorders →
Sponsor
Greater Houston Retina Research — full company profile →
Who can join
18 and older, any sex, with Diabetic Retinopathy or Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and 2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Liquid Biopsy Combined with Multi-Omics Approaches in Diagnosis, Management, and Progression of Diabetic Retinopathy.
Chen Q, Chen Y, Mou K, Zhang M. · · 2025 · cited 1× · PMID 40564025 · DOI 10.3390/biomedicines13061306
Verify or expand the search:
- PubMed search for NCT05333055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Retinopathy
Currently open trials in the same condition.
- NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
- NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting
Other Greater Houston Retina Research trials
Trials by the same sponsor.
- NCT05681884 — Safety and Efficacy of Faricimab in Patients With NPDR · Phase 2 · completed
- NCT04708145 — Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subje · Phase 4 · completed
- NCT03531294 — Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement · Phase 2 · completed
- NCT02299336 — Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05333055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Greater Houston Retina Research
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05333055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing